Study guide

15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups

Key Takeaways Explain This Topic AI

Version 9 lung staging applies to diagnoses from January 1, 2025; T categories are unchanged from the 8th edition (T1a 1 cm or less, T1b more than 1–2 cm, T1c more than 2–3 cm, T2a more than 3–4 cm, T2b more than 4–5 cm, T3 more than 5–7 cm, T4 more than 7 cm).

N2a is metastasis in a single ipsilateral mediastinal or subcarinal station, and N2b is metastasis in multiple ipsilateral mediastinal stations, with or without the subcarinal station.

M1c1 is multiple extrathoracic metastases in one organ system, and M1c2 is multiple extrathoracic metastases in several organ systems; both remain stage IVB.

Version 9 moved T1N1 from IIB to IIA, placed T1N2a in IIB, T2N2a and T3N2a in IIIA, and T2N2b in IIIB.

For part-solid adenocarcinomas, the clinical T category is based on the size of the solid (invasive) component, not the total size including ground glass.

Last updated: September 2026

Primary tumor (T)

T Definition

TX Primary tumor cannot be assessed, or tumor proven by malignant cells in sputum or washings but not seen by imaging or bronchoscopy (occult carcinoma)

  • T0 No evidence of primary tumor
  • Tis Carcinoma in situ: adenocarcinoma in situ (AIS) or squamous cell carcinoma in situ
  • T1 3 cm or less, surrounded by lung or visceral pleura, not more proximal than the lobar bronchus
  • T1mi Minimally invasive adenocarcinoma
  • T1a 1 cm or less
  • T1b More than 1 cm to 2 cm
  • T1c More than 2 cm to 3 cm

T2 More than 3 cm to 5 cm, or any of: involves the main bronchus without involving the carina; invades visceral pleura ; atelectasis or obstructive pneumonitis extending to the hilum

  • T2a More than 3 cm to 4 cm (or a T2 feature and 4 cm or less)
  • T2b More than 4 cm to 5 cm

T3 More than 5 cm to 7 cm, or invades parietal pleura or chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium, or separate tumor nodule(s) in the same lobe

T4 More than 7 cm, or invades diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body or carina, or separate nodule(s) in a different ipsilateral lobe

Version 9 changes to T: none to the categories. The wording was clarified for invasion of structures such as the azygos vein, vagus nerve, brachial plexus and thoracic nerve roots, which stay T3 or T4 as defined.

STORE note: occult lung carcinoma is assigned TX , according to the current AJCC definition.

Measurement rules

Part-solid (subsolid) adenocarcinoma: cT uses the size of the solid component on CT. AJCC's illustration shows a 10 mm part-solid nodule with an 8 mm solid part, which is cT1a . pT uses the size of the invasive component on pathology.

Pure ground-glass nodules of 3 cm or less that are adenocarcinoma in situ are Tis.

Round the size to the nearest millimeter. When the size is between two categories and uncertain, assign the lower T.

Regional lymph nodes (N)

  • N Definition
  • N0 No regional lymph node metastasis
  • N1 Ipsilateral peribronchial and/or hilar nodes and intrapulmonary nodes, including direct extension
  • N2a Single ipsilateral mediastinal or subcarinal nodal station
  • N2b Multiple ipsilateral mediastinal nodal stations, with or without the subcarinal station
  • N3 Contralateral mediastinal or hilar nodes; ipsilateral or contralateral scalene or supraclavicular nodes

Nodal stations follow the IASLC lymph node map. For example, station 7 is subcarinal and stations 2R and 4R are right upper and lower paratracheal. EBUS-TBNA and mediastinoscopy samples establish N2 or N3 (Section 10.1).

Distant metastasis (M)

  • M Definition
  • M0 No distant metastasis

M1a Separate nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules , or malignant pleural or pericardial effusion

  • M1b A single extrathoracic metastasis in a single organ, including a single non-regional node
  • M1c1 Multiple extrathoracic metastases in one organ system
  • M1c2 Multiple extrathoracic metastases in multiple organ systems

A pleural effusion that is cytologically negative on repeated exams, non-bloody, not an exudate, and judged unrelated to the tumor is excluded, and the case is not M1a on that basis.

Version 9 stage groups

  • Stage T and N (M0 unless shown)
  • Occult TX N0
  • 0 Tis N0
  • IA1 T1mi N0; T1a N0
  • IA2 T1b N0
  • IA3 T1c N0
  • IB T2a N0
  • IIA T2b N0; T1 (a–c) N1
  • IIB T2a–T2b N1; T3 N0; T1 N2a
  • IIIA T1 N2b; T2 N2a ; T3 N1; T3 N2a ; T4 N0; T4 N1
  • IIIB T2 N2b ; T3 N2b; T4 N2a; T4 N2b; T1–T2 N3
  • IIIC T3–T4 N3
  • IVA Any T, any N, M1a or M1b
  • IVB Any T, any N, M1c1 or M1c2

What changed from the 8th edition:

  • Combination 8th edition Version 9
  • T1 N1 IIB IIA
  • T1 N2 IIIA N2a IIB ; N2b IIIA
  • T2 N2 IIIA N2a IIIA; N2b IIIB
  • T3 N2 IIIB N2a IIIA ; N2b IIIB
  • M1c IVB M1c1 and M1c2 both IVB
  • Multiple lung tumors and staging

Staging and the Solid Tumor Rules answer different questions. First decide the number of primaries with the lung Solid Tumor Rules (Section 14.2). For a single primary with extra nodules, AJCC's multiple-nodule concepts are:

A separate nodule of the same histology in the same lobe is T3 .

A nodule in a different ipsilateral lobe is T4 .

A nodule in the contralateral lung is M1a .

Multifocal ground-glass or lepidic lesions: T is based on the highest T lesion, with (m) or the number of lesions.

Pneumonic-type adenocarcinoma: T is based on size, or T3/T4/M1a by the extent of lobes involved.

Worked cases

A 2.6 cm right lower lobe adenocarcinoma with a positive station 7 (subcarinal) node only, on EBUS: cT1c cN2a cM0 , which is stage IIB in Version 9 (IIIA in the 8th edition).

A 3.8 cm tumor with positive stations 4R and 7: T2a N2b M0 , stage IIIB .

A 1.8 cm tumor with a hilar node positive: T1b N1 M0 , stage IIA .

Brain and bone metastases (two organ systems): M1c2 , stage IVB .

A malignant pleural effusion: M1a , stage IVA .

Loading diagram... Lung Version 9 N and M decisions